Clinical Topics & News

Single Institution Retrospective Review of Patterns of Care and Disease Presentation in Female Veterans With Breast Cancer During the COVID-19 Pandemic


 

Background

Delays in care can impact patient satisfaction and survival outcomes. There are no studies in the literature evaluating the care continuum in veterans with breast cancer. A study of this predominantly African American female veteran population will help us understand barriers to care in this population.

Methods

A retrospective review of 87 patients diagnosed with breast cancer in the year 2021 at the Atlanta VA Medical Center was conducted to assess current care patterns as well as disease characteristics. Patients were included if their initial diagnostic evaluation and therapy for stage I-III breast cancer was at the Atlanta VA. Patients with a history of noncompliance causing delays in care were excluded from analysis. A total of 20 patients were identified for final analysis.

Results

Veterans were predominately African American (85%). Median age was 61 years. Stage at presentation was as follows: stage 1(35%) stage II (30%) and stage III (35%). Receptor status was as follows: hormone receptor positive (35%), Triple negative (35%), and HER-2/neu positive (30%). Genetic testing and genomic assays were completed in 100% of eligible patients per NCCN guidelines. Lumpectomy was performed in 44% of cases and mastectomy in 55% of cases. 40% of cases where mastectomy was performed were done for patient preference alone. Median time for various phases of care were as follows: symptomatic presentation to diagnostic imaging 48 days (range, 7-146), abnormal screening mammogram to diagnostic mammogram 6 days (range, 0-74), diagnostic imaging to diagnostic biopsy 15.5 days (range, 0-43), diagnostic biopsy to initiation of neoadjuvant systemic therapy 22 days (range, 14-31), diagnosis or completion of neoadjuvant systemic therapy to breast cancer surgery 58 days (range, 15-113), and surgery to initiation of adjuvant chemotherapy 33 days (range, 14-44).

Conclusions

In comparison to national statistics there was a higher incidence of HER-2/neu positivity (15% vs 30%) and triple negative (12% vs 35%) subtypes, highlighting the need for quicker diagnostic testing. The delay from symptomatic presentation to diagnostic mammogram and biopsy necessitates a response given that high-risk presentations account for 75% of the cases. These findings demonstrate the need for in-house mammography to care for this high-risk minority veteran population.

Recommended Reading

Hormone therapy didn’t increase recurrence or mortality in women treated for breast cancer
Federal Practitioner
Node-negative triple-negative breast cancer prognosis lies within stromal lymphocytes
Federal Practitioner
FDA approves trastuzumab-deruxtecan for HER2-low breast cancer
Federal Practitioner
Does PREDICT accurately estimate breast cancer survival?
Federal Practitioner
‘Flat denial’ can leave breast cancer patients with lasting scars
Federal Practitioner
Tumor-bed radiotherapy boost reduces DCIS recurrence risk
Federal Practitioner
Time to pull back on postsurgery radiation in breast cancer?
Federal Practitioner
Stronger evidence that exercise lowers breast cancer risk
Federal Practitioner
Sex is still a taboo subject for patients with breast cancer
Federal Practitioner
FDA warns of cancer risk in scar tissue around breast implants
Federal Practitioner